RecruitingNCT07330245

Achievement of LLDAS5 in Patients With Systemic Lupus Erythematosus Treated With Anifrolumab.

DAHLIA: Achievement of Low Level of Disease Activity With a Dose of Corticosteroids Less Than or Equal to 5 mg (LLDAS5): a Real-life Study With Anifrolumab on Patients With Systemic Lupus Erythematosus in Italy

Sponsor

AstraZeneca

Enrollment

218 participants

Start Date

Dec 31, 2025

Study Type

OBSERVATIONAL

Conditions

Lupus Erythematosus, Systemic

Summary

This is an observational, multicenter, prospective study on patients with systemic lupus erythematosus treated with anifrolumab in Italy aimed at evaluating the achievement of LLDAS5

Eligibility

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a biological treatment called Anifrolumab for people with lupus erythematosus, systemic. The study is currently recruiting participants at 19 locations.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BIOLOGICALAnifrolumab

anifrolumab - fully human monoclonal antibody target type I INF

Locations(22)

Azienda Ospedaliero-Universitaria di Cagliari Presidio di Monserrato

Monserrato, CA, Italy

Azienda Ospedaliero-Universitaria di Ferrara Arcispedale Sant'Anna

Cona, Ferrara, Italy

IRCCS Casa Sollievo della Sofferenza

San Giovanni Rotondo, Foggia, Italy

IRCCS Humanitas Research Hospital

Rozzano, Milano, Italy

AOU Ospedali Riuniti di Ancona - Presidio Torrette

Ancona, Italy

Azienda Ospedaliero-Universitaria Policlinico di Bari

Bari, Italy

ASST Spedali Civili di Brescia

Brescia, Italy

Azienda Ospedaliero-Universitaria Careggi

Florence, Italy

Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico

Milan, Italy

IRCCS Ospedale San Raffaele

Milan, Italy

Policlinico di Modena - AOU di Modena

Modena, Italy

Azienda Ospedaliera Universitaria "Luigi Vanvitelli"

Naples, Italy

Azienda Ospedaliera di Padova

Padova, Italy

Azienda Ospedaliera Universitaria Policlinico "Paolo Giaccone"

Palermo, Italy

Fondazione IRCCS Policlinico San Matteo

Pavia, Italy

Azienda Ospedaliero-Universitaria Pisana Ospedale Santa Chiara

Pisa, Italy

Policlinico Tor Vergata

Roma, Italy

Policlinico Umberto I - Sapienza Università di Roma

Roma, Italy

Azienda Ospedaliera Ordine Mauriziano Umberto I

Torino, Italy

Azienda Sanitaria Universitaria Giuliano Isontina (ASU GI) - Ospedale di Cattinara

Trieste, Italy

ASU Friuli Centrale - Ospedale Santa Maria della Misericordia di Udine

Udine, Italy

AOUI Verona - Ospedale Borgo Roma

Verona, Italy

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07330245

Related Trials

A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease

NCT0692554214 locations

A Research Trial to Assess if Cenerimod is Efficacious and Safe to Treat Active Lupus Nephritis on Top of Regular Treatment

NCT0720112914 locations

A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus

NCT07438496222 locations

A Study to Investigate the Safety, Tolerability, and Efficacy of AZD0120 in Adults With Refractory SLE

NCT0689793018 locations

NIS to Examine Disease Activity in SLE Patients Treated With Subcutaneous Anifrolumab in Routine Care

NCT0742426116 locations